{"id":4046,"date":"2019-02-05T12:33:25","date_gmt":"2019-02-05T07:03:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4046"},"modified":"2021-07-24T12:57:11","modified_gmt":"2021-07-24T07:27:11","slug":"notizia-89","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-89","title":{"rendered":"Notizia"},"content":{"rendered":"\n

FDA\ndiscards depression drug ALKS 5461 of Alkermes<\/strong><\/p>\n\n\n\n

The FDA <\/strong>has\u00a0rejected\u00a0approval for ALKS 5461<\/strong> of Alkermes <\/strong>in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine <\/strong>and samidorphan<\/strong>. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed improved results in people, who showed unresponsiveness to present antidepressant therapies. \u00a0Alkermes said that the FDA wanted more clinical data to give significant evidence for the effectiveness of ALKS 5461. <\/p>\n\n\n\n

An\natlas of HIV shows escape routes that could improve vaccine design<\/strong><\/p>\n\n\n\n

The scientists at the Fred Hutchinson Cancer Research Center <\/strong>made an atlas of HIV <\/a>mutations that gives insights on the ongoing search for an effective vaccine. The group showed that mutations can occur in the HIV envelope that is a layer of glycoproteins <\/strong>that transports the virus into host cells and interact with antibodies<\/strong>. Some drug makers have developed vaccines focused at triggering broadly neutralizing antibodies.<\/p>\n\n\n\n

J&J\nlaunches new intraocular lens for cataract patients <\/strong><\/p>\n\n\n\n

Johnson & Johnson<\/strong>, an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company, Vision has launched its TECNIS Eyhance intraocular lens for the cataract <\/a>patients in Europe. It is designed to provide vision at both intermediate and far distances. The lenses before offer better vision of objects at a distance, but cataract patients still require to wear glasses for performing the day-to-day tasks.  <\/p>\n\n\n\n

The\nvision loss gene therapy of GenSight flunks again<\/strong><\/p>\n\n\n\n

A phase 3 trial<\/strong> of GenSight<\/strong> Biologics\u2019 Leber hereditary optic neuropathy (LHON) gene therapy has\u00a0flunked\u00a0its primary endpoint. The AAV gene therapy was no better than placebo at improving vision at 48 weeks. France\u2019s GenSight designed GS010 <\/strong>to improve the vision of patients with a particular mutation in the mitochondrial ND4 gene and moved the gene therapy into a pair of phase 3 trials in 2016.<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA discards depression drug ALKS 5461 of Alkermes The FDA has\u00a0rejected\u00a0approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed improved results in people, who showed unresponsiveness to present antidepressant […]<\/p>\n","protected":false},"author":1,"featured_media":4047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1616,704,2521,297,341],"industry":[17225],"therapeutic_areas":[17235,17231,17244],"class_list":["post-4046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alkermes","tag-fda","tag-gensight","tag-hiv","tag-johnson-johnson","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-infectious-diseases","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"\nNotizia 05\/02\/2019 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-89\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 05\/02\/2019 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-89\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-05T07:03:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"759\" \/>\n\t<meta property=\"og:image:height\" content=\"422\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 05\/02\/2019 - DelveInsight Business Research LLP","description":"The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-89","og_locale":"en_US","og_type":"article","og_title":"Notizia 05\/02\/2019 - DelveInsight Business Research LLP","og_description":"The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-89","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-02-05T07:03:25+00:00","article_modified_time":"2021-07-24T07:27:11+00:00","og_image":[{"width":759,"height":422,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-89","url":"https:\/\/www.delveinsight.com\/blog\/notizia-89","name":"Notizia 05\/02\/2019 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-89#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-89#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs.jpg","datePublished":"2019-02-05T07:03:25+00:00","dateModified":"2021-07-24T07:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-89"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-89#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs.jpg","width":759,"height":422,"caption":"Kidney Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021655\/drugs-300x167.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alkermes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GenSight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson & Johnson<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alkermes<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GenSight<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">Johnson & Johnson<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 5, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 5, 2019 12:33 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Kidney Cancer","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4046"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4046\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4047"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4046"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4046"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}